October 10th Options Now Available For Moderna (MRNA)

The article details income-generating options strategies for Moderna (MRNA), currently trading at $24.54. Selling a $23.00 strike put, which is 6% out-of-the-money, could yield a 5.43% premium (46.13% annualized) with a 68% probability of expiring worthless, effectively lowering the cost basis to $21.75 if assigned. Alternatively, a $27.00 strike covered call, 10% out-of-the-money, could generate a 16.06% return if assigned by October 10th, or a 6.03% premium (51.19% annualized) if it expires worthless, with a 56% probability. These strategies offer defined risk/reward profiles for investors seeking to optimize returns on MRNA, with implied volatilities of 67% for the put and 79% for the call.

Analysis

The analysis centers on two specific options strategies for Moderna (MRNA), currently trading at $24.54 per share, aimed at income generation or acquiring shares at a discount. The first strategy involves selling a put option with a $23.00 strike price, which is approximately 6% out-of-the-money. This generates a premium of $1.25 per share, effectively lowering the cost basis to $21.75 if the option is exercised. Analytical data suggests a 68% probability of this put expiring worthless, in which case the seller retains the premium, realizing a 5.43% return on the cash commitment, or 46.13% annualized. The second strategy is a covered call, selling a $27.00 strike call against an existing stock position. This call, which is 10% out-of-the-money, yields a $1.48 premium and offers a total return of 16.06% if the stock is called away by the October 10th expiration, though it caps further upside. The probability of this call expiring worthless is cited as 56%, offering a 6.03% return boost, or 51.19% annualized, from the premium alone. Implied volatilities are elevated at 67% for the put and 79% for the call, notably higher than the trailing twelve-month historical volatility of 66%, indicating that options are priced for significant share price movement.

Key Decisions for Investors

• Investors seeking to acquire MRNA shares at a discount could consider selling the $23.00 put, which establishes a potential purchase price of $21.75 while generating immediate income.
• Current MRNA shareholders looking to enhance returns could sell the $27.00 covered call, which offers a 6.03% premium boost (51.19% annualized), but they must accept the risk of having their shares called away at $27.00, thereby capping potential gains.
• The elevated implied volatility, particularly the 79% in the call option versus 66% historical, suggests that option premiums are currently rich, presenting an attractive environment for option sellers but also signaling heightened market expectations of price swings.
• These strategies are purely technical; investors must supplement this analysis with their own fundamental research on Moderna's business prospects before committing capital, as the options' outcomes are entirely dependent on the underlying stock's performance.